CJC-1295 w/o DAC

Common questions about CJC-1295 w/o DAC

What is CJC-1295 without DAC?

CJC-1295 without DAC — also known as Modified GRF 1-29 (Mod-GRF) — is a short-acting GHRH analog without the DAC albumin-binding linker. It is studied as a pulsatile GH secretagogue and is commonly stacked with ipamorelin in research protocols.

Is CJC-1295 without DAC FDA-approved?

No. CJC-1295 without DAC is not approved by the FDA, MHRA, Health Canada, or the TGA. Research-peptide vendors sell it for laboratory research only.

What is the half-life of CJC-1295 without DAC?

Published reports describe a plasma half-life of approximately 30 minutes, which is why this variant requires frequent dosing for sustained GH elevation, in contrast to the multi-day half-life of the DAC-linked form.

What dose of CJC-1295 without DAC is used in research?

Doses reported in published preclinical and early human studies vary by endpoint and dosing schedule. Pepticker does not publish a dosing protocol — refer to the original literature for the specific study you are reproducing.

What is CJC-1295 without DAC commonly stacked with?

The most widely discussed stack is CJC-1295 without DAC plus ipamorelin — pairing pulsatile GHRH-arm and ghrelin-arm activity in a way that mirrors endogenous GH-release patterns more closely than either compound alone.

How is CJC-1295 without DAC different from CJC-1295 with DAC?

The DAC linker is the only structural difference. Without DAC, the half-life is roughly 30 minutes and the compound supports a pulsatile dosing pattern; with DAC, the half-life extends to days through albumin binding and produces a sustained-elevation pattern.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.